• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由于相同的纯合R169Q突变导致的ADA2缺乏症患者的表型变异性。

Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations.

作者信息

Van Montfrans Joris M, Hartman Esther A R, Braun Kees P J, Hennekam Eric A M, Hak Elisabeth A, Nederkoorn Paul J, Westendorp Willeke F, Bredius Robbert G M, Kollen Wouter J W, Schölvinck Elisabeth H, Legger G Elizabeth, Meyts Isabelle, Liston Adrian, Lichtenbelt Klaske D, Giltay Jacques C, Van Haaften Gijs, De Vries Simons Gaby M, Leavis Helen, Sanders Cornelis J G, Bierings Marc B, Nierkens Stefan, Van Gijn Marielle E

机构信息

Department of Pediatric Immunology and Infectious Diseases,

Department of Pediatric Immunology and Infectious Diseases.

出版信息

Rheumatology (Oxford). 2016 May;55(5):902-10. doi: 10.1093/rheumatology/kev439. Epub 2016 Feb 10.

DOI:10.1093/rheumatology/kev439
PMID:26867732
Abstract

OBJECTIVE

To determine the genotype-phenotype association in patients with adenosine deaminase-2 (ADA2) deficiency due to identical homozygous R169Q mutations inCECR1 METHODS: We present a case series of nine ADA2-deficient patients with an identical homozygous R169Q mutation. Clinical and diagnostic data were collected and available MRI studies were reviewed. We performed genealogy and haplotype analyses and measured serum ADA2 activity. ADA2 activity values were correlated to clinical symptoms.

RESULTS

Age of presentation differed widely between the nine presented patients (range: 0 months to 8 years). The main clinical manifestations were (hepato)splenomegaly (8/9), skin involvement (8/9) and neurological involvement (8/9, of whom 6 encountered stroke). Considerable variation was seen in type, frequency and intensity of other symptoms, which included aplastic anaemia, acute myeloid leukaemia and cutaneous ulcers. Common laboratory abnormalities included cytopenias and hypogammaglobulinaemia. ADA2 enzyme activity in patients was significantly decreased compared with healthy controls. ADA2 activity levels tended to be lower in patients with stroke compared with patients without stroke. Genealogical studies did not identify a common ancestor; however, based on allele frequency, a North-West European founder effect can be noted. Three patients underwent haematopoietic cell transplantation, after which ADA2 activity was restored and clinical symptoms resolved.

CONCLUSION

This case series revealed large phenotypic variability in patients with ADA2 deficiency though they were homozygous for the same R169Q mutation inCECR1 Disease modifiers, including epigenetic and environmental factors, thus seem important in determining the phenotype. Furthermore, haematopoietic cell transplantation appears promising for those patients with a severe clinical phenotype.

摘要

目的

确定由于 CECR1 基因中相同的纯合 R169Q 突变导致腺苷脱氨酶 2(ADA2)缺乏患者的基因型 - 表型关联。

方法

我们报告了一组 9 例具有相同纯合 R169Q 突变的 ADA2 缺乏患者。收集了临床和诊断数据,并回顾了现有的 MRI 研究。我们进行了系谱和单倍型分析,并测量了血清 ADA2 活性。将 ADA2 活性值与临床症状相关联。

结果

9 例患者的发病年龄差异很大(范围:0 个月至 8 岁)。主要临床表现为(肝)脾肿大(8/9)、皮肤受累(8/9)和神经受累(8/9,其中 6 例发生中风)。其他症状的类型、频率和强度存在相当大的差异,包括再生障碍性贫血、急性髓系白血病和皮肤溃疡。常见的实验室异常包括血细胞减少和低丙种球蛋白血症。与健康对照相比,患者的 ADA2 酶活性显著降低。与未发生中风的患者相比,发生中风的患者 ADA2 活性水平往往较低。系谱研究未发现共同祖先;然而,基于等位基因频率,可以注意到西北欧奠基者效应。3 例患者接受了造血细胞移植,移植后 ADA2 活性恢复,临床症状缓解。

结论

该病例系列显示,尽管 CECR1 基因中相同的 R169Q 突变呈纯合状态,但 ADA2 缺乏患者的表型变异很大。因此,包括表观遗传和环境因素在内的疾病修饰因子在决定表型方面似乎很重要。此外,造血细胞移植对于那些具有严重临床表型的患者似乎很有前景。

相似文献

1
Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations.由于相同的纯合R169Q突变导致的ADA2缺乏症患者的表型变异性。
Rheumatology (Oxford). 2016 May;55(5):902-10. doi: 10.1093/rheumatology/kev439. Epub 2016 Feb 10.
2
Deficiency of Adenosine Deaminase Type 2: A Description of Phenotype and Genotype in Fifteen Cases.腺苷脱氨酶 2 缺乏症:15 例表型和基因型描述。
Arthritis Rheumatol. 2016 Sep;68(9):2314-22. doi: 10.1002/art.39699.
3
A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2.一种具有多种表型的单基因疾病:腺苷脱氨酶 2 缺乏症。
J Rheumatol. 2020 Jan;47(1):117-125. doi: 10.3899/jrheum.181384. Epub 2019 May 1.
4
Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation.携带新型CECR1突变的腺苷脱氨酶2缺乏症两兄弟中的具有I型干扰素特征的自身免疫表型。
Pediatr Rheumatol Online J. 2017 Aug 22;15(1):67. doi: 10.1186/s12969-017-0193-x.
5
[Multiple facets of ADA2 deficiency: Vasculitis, auto-inflammatory disease and immunodeficiency: A literature review of 135 cases from literature].[ADA2缺乏症的多方面表现:血管炎、自身炎症性疾病和免疫缺陷:对文献中135例病例的综述]
Rev Med Interne. 2018 Apr;39(4):297-306. doi: 10.1016/j.revmed.2017.11.006. Epub 2017 Dec 19.
6
ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study.ADA2 缺陷(DADA2)作为早发性多动脉炎和卒中的一个未被识别病因:一项多中心全国性研究。
Ann Rheum Dis. 2017 Oct;76(10):1648-1656. doi: 10.1136/annrheumdis-2016-210802. Epub 2017 May 18.
7
Mutations in CECR1 associated with a neutrophil signature in peripheral blood.与外周血中性粒细胞特征相关的CECR1突变。
Pediatr Rheumatol Online J. 2014 Sep 24;12:44. doi: 10.1186/1546-0096-12-44. eCollection 2014.
8
Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2.ADA2 缺陷症中作为疾病机制的紊乱 N-连接糖基化。
J Allergy Clin Immunol. 2018 Oct;142(4):1363-1365.e8. doi: 10.1016/j.jaci.2018.05.038. Epub 2018 Jun 21.
9
Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency.ADA2 缺陷症三例死亡和五例存活病例的临床、影像学和基因特征。
Rheumatol Int. 2018 Jan;38(1):129-136. doi: 10.1007/s00296-017-3740-3. Epub 2017 May 17.
10
Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency.造血干细胞移植可挽救腺苷脱氨酶2缺乏症患者的免疫表型并预防血管病变。
J Allergy Clin Immunol. 2015 Jan;135(1):283-7.e5. doi: 10.1016/j.jaci.2014.10.010. Epub 2014 Nov 25.

引用本文的文献

1
Dominant negative ADA2 mutations cause ADA2 deficiency in heterozygous carriers.显性负性ADA2突变导致杂合子携带者出现ADA2缺乏症。
J Exp Med. 2025 Nov 3;222(11). doi: 10.1084/jem.20250499. Epub 2025 Aug 27.
2
Getting to know adenosine deaminase 2 deficiency inside and out.全面了解腺苷脱氨酶2缺乏症
J Allergy Clin Immunol. 2025 May;155(5):1451-1463. doi: 10.1016/j.jaci.2025.01.040. Epub 2025 Feb 14.
3
Dominant negative mutations cause ADA2 deficiency in heterozygous carriers.显性负性突变导致杂合子携带者出现ADA2缺乏症。
medRxiv. 2024 Dec 11:2024.12.09.24317629. doi: 10.1101/2024.12.09.24317629.
4
Rare primary vasculitis: update on multiple complex diseases and the new kids on the block.罕见原发性血管炎:多种复杂疾病的最新进展和崭露头角的新疾病。
Adv Rheumatol. 2024 Oct 9;64(1):79. doi: 10.1186/s42358-024-00421-8.
5
Development of EBV Related Diffuse Large B-cell Lymphoma in Deficiency of Adenosine Deaminase 2 with Uncontrolled EBV Infection.腺苷脱氨酶 2 缺乏伴 EBV 感染失控导致 EBV 相关弥漫性大 B 细胞淋巴瘤的发生。
J Clin Immunol. 2024 May 17;44(5):118. doi: 10.1007/s10875-024-01712-x.
6
Vasculitis and vasculopathy associated with inborn errors of immunity: an overview.与遗传性免疫缺陷相关的血管炎和血管病变:概述
Front Pediatr. 2024 Jan 31;11:1258301. doi: 10.3389/fped.2023.1258301. eCollection 2023.
7
Review of T cell proliferation regulatory factors in treatment and prognostic prediction for solid tumors.实体瘤治疗及预后预测中T细胞增殖调节因子的综述
Heliyon. 2023 Oct 29;9(11):e21329. doi: 10.1016/j.heliyon.2023.e21329. eCollection 2023 Nov.
8
Deficiency of adenosine deaminase 2 as an unrecognized cause of early-onset stroke and cranial nerve palsy.腺苷脱氨酶2缺乏作为早发性中风和颅神经麻痹的一种未被认识的病因
North Clin Istanb. 2023 Aug 2;10(4):411-417. doi: 10.14744/nci.2022.45380. eCollection 2023.
9
Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study.腺苷脱氨酶 2 缺乏症患者的神经表型:一项队列研究。
Eur J Neurol. 2024 Jan;31(1):e16043. doi: 10.1111/ene.16043. Epub 2023 Aug 29.
10
A case series of ten plus one deficiency of adenosine deaminase 2 (DADA2) patients in Iran.伊朗十加一腺苷脱氨酶 2 (DADA2) 缺乏症患者病例系列。
Pediatr Rheumatol Online J. 2023 Jun 13;21(1):55. doi: 10.1186/s12969-023-00838-3.